• Effects of gene therapy were stable up to 11 years, but with variable outcomes based on the levels of engrafted, gene-corrected stem cells.

  • Integration site analyses showed some prominent clones with integrants near proto-oncogenes, but no clinically significant clonal outgrowth.

Patients lacking functional adenosine deaminase activity have severe combined immunodeficiency (ADA SCID), which can be treated with ADA enzyme replacement therapy (ERT), allogeneic hematopoietic stem cell transplantation (HSCT), or autologous HSCT with gene-corrected cells (gene therapy [GT]). A cohort of 10 ADA SCID patients, aged 3 months to 15 years, underwent GT in a phase 2 clinical trial between 2009 and 2012. Autologous bone marrow CD34+ cells were transduced ex vivo with the MND (myeloproliferative sarcoma virus, negative control region deleted, dl587rev primer binding site)–ADA gammaretroviral vector (gRV) and infused following busulfan reduced-intensity conditioning. These patients were monitored in a long-term follow-up protocol over 8 to 11 years. Nine of 10 patients have sufficient immune reconstitution to protect against serious infections and have not needed to resume ERT or proceed to secondary allogeneic HSCT. ERT was restarted 6 months after GT in the oldest patient who had no evidence of benefit from GT. Four of 9 evaluable patients with the highest gene marking and B-cell numbers remain off immunoglobulin replacement therapy and responded to vaccines. There were broad ranges of responses in normalization of ADA enzyme activity and adenine metabolites in blood cells and levels of cellular and humoral immune reconstitution. Outcomes were generally better in younger patients and those receiving higher doses of gene-marked CD34+ cells. No patient experienced a leukoproliferative event after GT, despite persisting prominent clones with vector integrations adjacent to proto-oncogenes. These long-term findings demonstrate enduring efficacy of GT for ADA SCID but also highlight risks of genotoxicity with gRVs. This trial was registered at www.clinicaltrials.gov as #NCT00794508.

1.
Giblett
ER
,
Anderson
JE
,
Cohen
F
,
Pollara
B
,
Meuwissen
HJ.
Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity
.
Lancet.
1972
;
2
(
7786
):
1067
-
1069
.
2.
Hershfield
M
,
Adam
MP
,
Ardinger
HH
, et al
.
Adenosine deaminase deficiency
. pubmed.ncbi.nlm.nih.gov/20301656/. Accessed August 30, 2020.
3.
Blackburn
MR
,
Kellems
RE.
Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation
.
Adv Immunol.
2005
;
86
(
1
):
41
.
4.
Kohn
DB
,
Hershfield
MS
,
Puck
JM
, et al
.
Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency
.
J Allergy Clin Immunol.
2019
;
143
(
3
):
852
-
863
.
5.
Parkman
R
,
Gelfand
EW
,
Rosen
FS
,
Sanderson
A
,
Hirschhorn
R.
Severe combined immunodeficiency and adenosine deaminase deficiency
.
N Engl J Med.
1975
;
292
(
14
):
714
-
719
.
6.
Hassan
A
,
Booth
C
,
Brightwell
A
, et al;
Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency
.
Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency
.
Blood.
2012
;
120
(
17
):
3615
-
3624, quiz 3626
.
7.
Chan
B
,
Wara
D
,
Bastian
J
, et al
.
Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID)
.
Clin Immunol.
2005
;
117
(
2
):
133
-
143
.
8.
Aiuti
A
,
Slavin
S
,
Aker
M
, et al
.
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
.
Science.
2002
;
296
(
5577
):
2410
-
2413
.
9.
Aiuti
A
,
Cattaneo
F
,
Galimberti
S
, et al
.
Gene therapy for immunodeficiency due to adenosine deaminase deficiency
.
N Engl J Med.
2009
;
360
(
5
):
447
-
458
.
10.
Cicalese
MP
,
Ferrua
F
,
Castagnaro
L
, et al
.
Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety
.
Mol Ther.
2018
;
26
(
3
):
917
-
931
.
11.
Gaspar
HB
,
Bjorkegren
E
,
Parsley
K
, et al
.
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning
.
Mol Ther.
2006
;
14
(
4
):
505
-
513
.
12.
Candotti
F
,
Shaw
KL
,
Muul
L
, et al
.
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans
.
Blood.
2012
;
120
(
18
):
3635
-
3646
.
13.
Shaw
KL
,
Garabedian
E
,
Mishra
S
, et al
.
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency
.
J Clin Invest.
2017
;
127
(
5
):
1689
-
1699
.
14.
Cavazzana-Calvo
M
,
Thrasher
A
,
Mavilio
F.
The future of gene therapy
.
Nature.
2004
;
427
(
6977
):
779
-
781
.
15.
Bushman
FD.
Retroviral integration and human gene therapy
.
J Clin Invest.
2007
;
117
(
8
):
2083
-
2086
.
16.
Berry
CC
,
Gillet
NA
,
Melamed
A
,
Gormley
N
,
Bangham
CR
,
Bushman
FD.
Estimating abundances of retroviral insertion sites from DNA fragment length data
.
Bioinformatics.
2012
;
28
(
6
):
755
-
762
.
17.
Berry
CC
,
Nobles
C
,
Six
E
, et al
.
INSPIIRED: quantification and visualization tools for analyzing integration site distributions
.
Mol Ther Methods Clin Dev.
2016
;
4
:
17
-
26
.
18.
Sherman
E
,
Nobles
C
,
Berry
CC
, et al
.
INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes
.
Mol Ther Methods Clin Dev.
2016
;
4
:
39
-
49
.
19.
Kohn
DB
,
Kantoff
PW
,
Eglitis
M
, et al
.
Retrovirus-mediated gene transfer into mammalian cells
.
Blood Cells.
1987
;
13
:
285
-
296
.
20.
Hershfield
MS
,
Fetter
JE
,
Small
WC
, et al
.
Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells
.
J Biol Chem.
1982
;
257
(
11
):
6380
-
6386
.
21.
Shearer
WT
,
Rosenblatt
HM
,
Gelman
RS
, et al;
Pediatric AIDS Clinical Trials Group
.
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study
.
J Allergy Clin Immunol.
2003
;
112
(
5
):
973
-
980
.
22.
Agarwal
S
,
Cunningham-Rundles
C.
Assessment and clinical interpretation of reduced IgG values
.
Ann Allergy Asthma Immunol.
2007
;
99
(
3
):
281
-
283
.
23.
Ritz
C
,
Meng
W
,
Stanley
NL
, et al
.
Postvaccination graft dysfunction/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes [correction published in Blood Adv. 2020;4(13):2865]
.
Blood Adv.
2020
;
4
(
7
):
1378
-
1382
.
24.
Meng
W
,
Zhang
B
,
Schwartz
GW
, et al
.
An atlas of B-cell clonal distribution in the human body
.
Nat Biotechnol.
2017
;
35
(
9
):
879
-
884
.
25.
Krishnamoorthy
K
,
Lee
M.
Improved tests for the equality of normal coefficients of variation
.
Comput Stat.
2013
;
29
(
1-2
):
215
-
232
.
26.
R Core Team, Foundation for Statistical Computing
.
R: A language and environment for statistical computing
. www.R-project.org. Accessed August 30, 2020.
27.
Cooper
AR
,
Lill
GR
,
Shaw
K
, et al
.
Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients
.
Blood.
2017
;
129
(
19
):
2624
-
2635
.
28.
Hacein-Bey-Abina
S
,
Von Kalle
C
,
Schmidt
M
, et al
.
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
.
Science.
2003
;
302
(
5644
):
415
-
419
.
29.
Hacein-Bey-Abina
S
,
Garrigue
A
,
Wang
GP
, et al
.
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
.
J Clin Invest.
2008
;
118
(
9
):
3132
-
3142
.
30.
Six
E
,
Gandemer
V
,
Maganini
A
, et al
.
LOMO2 associated clonal T cell proliferation 15 years after gamma-retroviral mediated gene therapy for SCIDX1
.
Mol Ther.
2017
;
25
(
5 suppl 1
):
347
.
31.
Howe
SJ
,
Mansour
MR
,
Schwarzwaelder
K
, et al
.
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
.
J Clin Invest.
2008
;
118
(
9
):
3143
-
3150
.
32.
Stein
S
,
Ott
MG
,
Schultze-Strasser
S
, et al
.
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
.
Nat Med.
2010
;
16
(
2
):
198
-
204
.
33.
Braun
CJ
,
Boztug
K
,
Paruzynski
A
, et al
.
Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity
.
Sci Transl Med.
2014
;
6
(
227
):
227ra33
.
34.
van Leeuwen
JE
,
van Tol
MJ
,
Joosten
AM
, et al
.
Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency
.
Blood.
1994
;
84
(
11
):
3936
-
3947
.
35.
Buckley
RH
,
Schiff
SE
,
Schiff
RI
, et al
.
Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency
.
N Engl J Med.
1999
;
340
(
7
):
508
-
516
.
36.
Fischer
A.
Thirty years of bone marrow transplantation for severe combined immunodeficiency
.
N Engl J Med.
1999
;
340
(
7
):
559
-
561
.
37.
Rappeport
JM
,
O’Reilly
RJ
,
Kapoor
N
,
Parkman
R.
Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us
.
Immunol Allergy Clin North Am.
2010
;
30
(
1
):
17
-
30
.
38.
Aiuti
A
,
Cassani
B
,
Andolfi
G
, et al
.
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy
.
J Clin Invest.
2007
;
117
(
8
):
2233
-
2240
.
39.
Biasco
L
,
Ambrosi
A
,
Pellin
D
, et al
.
Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell
.
EMBO Mol Med.
2011
;
3
(
2
):
89
-
101
.
40.
Bradford
KL
,
Liu
S
,
Krajinovic
M
, et al
.
Busulfan pharmacokinetics in adenosine deaminase-deficient severe combined immunodeficiency gene therapy
.
Biol Blood Marrow Transplant.
2020
;
26
(
10
):
1819
-
1827
.
41.
Case
SS
,
Price
MA
,
Jordan
CT
, et al
.
Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors
.
Proc Natl Acad Sci USA.
1999
;
96
(
6
):
2988
-
2993
.
42.
Ferrari
G
,
Thrasher
AJ
,
Aiuti
A.
Gene therapy using haematopoietic stem and progenitor cells
.
Nat Rev Genet.
2021
;
22
(
4
):
216
-
234
.
43.
Staal
FJT
,
Aiuti
A
,
Cavazzana
M.
Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives
.
Front Pediatr.
2019
;
7
:
443
.
44.
Kohn
DB
,
Booth
C
,
Shaw
KL
, et al
.
Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency
.
N Engl J Med.
2021
;
384(21)
:
2002
-
2013
.
You do not currently have access to this content.

Sign in via your Institution

Sign In